Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis.

Background: Hemophilia A (HA) is predominantly associated with males due to X-linked inheritance. Males and females with HA have shared unmet medical needs, highlighting the necessity for comprehensive care irrespective of sex.

Objectives: This analysis investigated the efficacy and safety of emicizumab prophylaxis in 3 females with HA.

Outcomes and management of pregnancy in women with bleeding disorder of unknown cause.

Background: Patients with a bleeding tendency with normal laboratory tests have been described as having an unclassified bleeding disorder or bleeding disorder of unknown cause (BDUC). There are very little data available on how to manage pregnancy.

Objectives: To study management and outcomes of these patients at four United Kingdom hemophilia comprehensive care centers.

Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders.

Background: Bleeding of unknown cause (BUC) and unclassified bleeding disorders (UBD) are increasingly recognized. There is no guidance on diagnosis and management.

Objectives: To examine UK haemophilia centre registration patterns and current practice for UBD patients.

Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies.

Unlabelled: Unclassified bleeding disorders account for 2.6% of all new bleeding disorder registrations in the UK. The management of the bleeding phenotype associated with these disorders is poorly described.

Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?

Introduction: One of the most often stated tenets of haemophilia care is that prophylaxis converts a person from a severe to a moderate phenotype. In this review, we argue that this is not an accurate assumption and that people on prophylaxis predominantly have factor VIII/IX levels in the mild range.

Moderate Haemophilia And Prophylaxis: People with moderate haemophilia, who are treating with on-demand regimens, experience joint bleeds and often develop significant arthropathy.